Arbovirus fever

This trial is testing whether a single injection of an experimental chikungunya vaccine, VLA1553, is safe and triggers a protective immune response in healthy children aged 1 to 11 years. About 300 children will receive either a full dose, a half dose, or a control vaccine. The s…

This study tested a single-dose chikungunya vaccine (VLA1553) in about 750 teenagers aged 12 to 17. The goal was to see if the vaccine safely produces enough antibodies to protect against the virus. Participants received either the vaccine or a placebo, and their immune responses…

This early-stage trial tested two new vaccines—one for yellow fever and one for rabies—in 112 healthy adults aged 18 to 40. The main goal was to check safety and see how well the vaccines trigger an immune response. Participants received different doses or a placebo to help find …

This study tested an inactivated chikungunya virus vaccine called HydroVax-005 CHIKV in 48 healthy adults aged 18 to 49. Participants received two doses of either a low or high dose of the vaccine or a placebo. The main goal was to check safety and how well the vaccine triggers a…

This early-stage study tested a new yellow fever vaccine (MVA-BN-YF) in 92 healthy adults aged 18-45. Some volunteers received the vaccine alone, some with an adjuvant (ISA 720) to boost the immune response, and others received a placebo or a different vaccine. The main goal was …

This study tested a new yellow fever vaccine (vYF) to see if it is as safe as the current licensed vaccine (YF-VAX). A total of 640 healthy adults aged 18 to 60 received a single shot of either vaccine. Researchers monitored side effects like pain, fever, and headache for about 6…

This study tested a yellow fever vaccine in 254 healthy adults aged 18 and older in Japan. Participants received one shot under the skin and were followed for about a month. The goal was to see if the vaccine triggers a strong immune response and is safe.

This Phase 1 study tested a new yellow fever vaccine (vYF) in 73 healthy adults aged 18 to 60. The goal was to check the vaccine's safety and how well it triggers an immune response at three different doses. Participants were monitored for side effects and antibody levels over si…

This Phase 1 trial tested an inactivated yellow fever vaccine called HydroVax-002 YFV in 26 healthy adults. Participants received two doses of either the vaccine or a placebo. The main goal was to check safety and side effects, while also measuring immune response. The trial is c…

This study tested whether sending health tips via WhatsApp could help families in Colombia prevent dengue, Zika, and chikungunya. About 900 households were split into three groups: one got WhatsApp messages plus community support, one got community support only, and one got routi…

This study tested whether smaller doses of the yellow fever vaccine are as safe and effective as the standard dose. Researchers gave 88 healthy adults either the full dose or a reduced dose (one-fifth or one-tenth the size). They monitored side effects and measured immune respons…

This study tested a clever way to prevent dengue fever: releasing mosquitoes infected with Wolbachia bacteria into neighborhoods in Brazil. Over four years, researchers compared areas that got these special mosquitoes plus usual control methods to areas with usual methods alone. …

This study tested whether spraying insecticide on indoor walls (Targeted Indoor Residual Spraying) can prevent diseases spread by Aedes mosquitoes, like dengue, chikungunya, and Zika. Over 4,400 children aged 2 to 15 in Merida, Mexico took part. Researchers tracked how many got s…

This large study tested a device called Mosquito Shield that releases a repellent (transfluthrin) to keep mosquitoes away. Nearly 7,000 children aged 4-16 in Sri Lanka took part. The goal was to see if the device reduces infections from viruses like dengue. Researchers tracked in…

This study followed 775 healthy children aged 2-9 in Cambodia over three years to learn how mosquitoes spread dengue and other viruses. Researchers took blood samples every wet and dry season to check for past or current infections. The goal was to understand why young children g…

This pilot study tests a new technology called inDrop RNA-Seq to analyze individual immune cells in detail. Researchers will use it to study how healthy adults respond to the yellow fever vaccine, which is known to be very effective. The goal is to identify the specific cell type…

This study checks in on 152 people from Reunion Island who had Chikungunya during the 2005-2006 outbreak. Researchers want to classify the types of joint pain and swelling that persist 15 years after infection. Participants undergo a rheumatology exam and questionnaire to see if …

This early-stage study tested a single dose of an experimental drug called SAR440894 in 42 healthy adults to see if it was safe. The goal was not to treat the disease but to gather initial safety information before testing it in people with chikungunya virus infection. Participan…

This study looked at how past infections and damage to lymph node structures might weaken the body's long-term immune response to the yellow fever vaccine. Researchers enrolled 43 healthy adults in Uganda and Minnesota, collecting blood and lymph node samples before and after vac…

This study gave 239 healthy adults the yellow fever vaccine to learn how the immune system fights viral infections. Researchers measured the strength and quality of T cell responses over up to one year. The goal was to understand immune reactions, not to test the vaccine itself, …